UroGen Pharma (URGN) Other Accumulated Expenses (2017 - 2026)

UroGen Pharma (URGN) has reported Other Accumulated Expenses for 10 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• Quarterly Other Accumulated Expenses rose 15.73% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 15.73% YoY) and the FY2025 annual result came in at $5.2 million, down 34.76% from the prior year.
• Other Accumulated Expenses grew to $5.5 million in Q1 2026 per URGN's latest filing, from $5.2 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for URGN reached as high as $7.9 million in Q4 2024 and fell as low as $3.0 million in Q2 2022.
• A 5-year average of $4.2 million and a median of $3.9 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 131.07% — and 2025, when it tumbled 34.76%.
• Year by year, Other Accumulated Expenses stood at $3.3 million in 2022, then gained by 17.83% to $3.9 million in 2023, then jumped by 105.91% to $7.9 million in 2024, then plunged by 34.76% to $5.2 million in 2025, then advanced by 5.15% to $5.5 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $5.5 million, $5.2 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.